Martini Jeffrey S 4

What Happened
Jeffrey S. Martini, Chief Scientific Officer of Palvella Therapeutics (PVLA), was granted a derivative equity award covering 64,318 shares on 2026-02-05. The Form 4 reports an acquisition at $0.00 (no cash paid at grant). The award is recorded as a derivative (option) rather than an immediate stock purchase or sale.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely filing).
• Transaction type/code: A (Award/Grant of a derivative security).
• Shares/units granted: 64,318 (report shows $0.00 paid at grant).
• Vesting: The option vests in equal monthly installments over 48 months beginning February 5, 2026, subject to continuous service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• No exercise or sale occurred—this is a grant of an option-like award, not a cash transaction.

Context This is a standard equity compensation grant to an executive. Because it’s a derivative award that vests over time, it does not represent an immediate purchase or sale of shares and does not by itself indicate a short-term trading signal. The award requires continued service to vest, and the shares are not immediately exercisable/saleable until vested per the stated schedule.